SAN DIEGO and VANCOUVER, British Columbia, March 23, 2017 /PRNewswire/ -- Sophiris Bio
Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a clinical
late-stage biopharmaceutical company developing topsalysin (PRX302)
for the treatment of urological diseases, today announced that data
from its successful Phase 2a study of topsalysin, which evaluated
the drug as a focal treatment for localized prostate cancer, will
be presented as a poster on March 26,
2017 at the 32nd Annual European Association of
Urology in London, UK. The poster
has been selected by conference organizers as one of the best
posters at the congress.
Abstract No. 758: "Intra-prostatic injection of PRX302 to
focally ablate clinically significant prostate cancer: An open
label, phase 2a study"
Presenting Author: Dr. Yaalini Shanmugabavan, Division
of Surgery and Interventional Sciences, University College London,
London, UK
Poster Session: Poster Session 57 – Prostate cancer:
Is the future focal?
Time: March 26, 2017 from 3:45
pm – 5:15 pm GMT
The abstract related to the poster can be accessed through the
European Association of Urology Congress website at
http://eau17.uroweb.org/.
About Sophiris
Sophiris Bio Inc. is a
biopharmaceutical company developing topsalysin (PRX302) for the
treatment of patients with urological diseases. Topsalysin is in
Phase 2 clinical development for the focal treatment of localized
prostate cancer as well as Phase 3 clinical development for the
treatment of lower urinary tract symptoms of benign prostatic
hyperplasia (BPH). Topsalysin is a highly potent ablative agent
that is selective and targeted in that it is only activated by
enzymatically active PSA which is found in high concentrations in
the transition zone of the prostate and in and around prostate
tumor cells. More than 400 patients have received treatment
with topsalysin, which continues to appear to be safe and well
tolerated. For more information, please visit
www.sophirisbio.com.
Company Contact:
Peter
Slover
Chief Financial Officer
(858) 777-1760
Corporate Communications and Media
Contact:
Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/topsalysin-data-from-successful-phase-2a-localized-prostate-cancer-study-to-be-presented-at-the-32nd-european-association-of-urology-congress-300428644.html
SOURCE Sophiris Bio Inc.